RICHMOND, Va., Sep 15, 2003 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ:INSM) today announced that its Phase III drug candidate, rhIGF-I/rhIGFBP-3, will be featured in two podium presentation at the 42nd Annual Meeting of the European Society for Paediatric Endocrinolgy in Ljubljana, Slovenia, September 18-21.
Ceclia Camacho-Hubner, M.D., of St. Bartholemew's Hospital, London, United Kingdom, will give the oral presentation entitled, "Recombinant Human Insulin-Like Growth Factor (IGF)-I/IGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome." This data was presented to The Endocrine Society's Annual Meeting, ENDO 2003.
Tero Saukkonen, M.D., Division of Endocrinology and Diabetes, Hospital for Children and Adolescents, University of Helsinki, will give a second podium presentation entitled, "Effects of Combined Recombinant Human Insulin-Like Growth Factor I / Insulin-Like Growth Factor Binding Protein 3 on Growth Hormone Secretion & Insulin Sensitivity in Adolescents with Type I Diabetes." This data is an extension of a study that was previously presented at the 63rd Scientific Sessions of the ADA.
Rachel Williams, M.D., Clinical Research Fellow, Department of Paediatrics, University of Cambridge will present a third abstract entitled, "The Effects of Administration of IGF-I/IGFBP-3 Complex (SomatoKine) on Levels of IGF-I and IGFBP-3 and on IGFBP-3 Proteolysis in Type 1 Diabetes."
42nd European Society for Paediatric Endocrinology Abstracts:
- Abstract OR5-48: "Recombinant Human Insulin-Like Growth Factor (IGF)-I/IGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome" Session: GH/IGF-I, Friday, September 19, 9:45am
- Abstract OR4-45: "Effects of Combined Recombinant Human Insulin-Like Growth Factor I / Insulin-Like Growth Factor Binding Protein 3 on Growth Hormone Secretion & Insulin Sensitivity in Adolescents with Type I Diabetes" Session: Glucose Metabolism, Friday, September 19, 9:45am
- Abstract P2-243: "The Effects of Administration of IGF-I/IGFBP-3 Complex (SomatoKine) on Levels of IGF-I and IGFBP-3 and on IGFBP-3 Proteolysis in Type 1 Diabetes" Session: IGF's, IGFBP's and Growth Factors, Saturday, September 20.
These abstracts will be available on Insmed's corporate website, www.insmed.com, on Friday, September 19.
More on rhIGF-I/rhIGFBP-3
Insmed's rhIGF-I/rhIGFBP-3 is a proprietary delivery composition of insulin-like growth factor-I (IGF-I). The novel compound is administered as a once-daily subcutaneous injection, which can restore IGF levels to physiological relevant levels. In diabetic subjects, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in blood sugar control and a significant reduction in daily insulin use. Following severe burn injury, in both children and adults, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in muscle protein synthesis and a significant reduction in the inflammatory response associated with the trauma. In recovery from hip fractures, administration of rhIGF-I/rhIGFBP-3 has demonstrated a significant improvement in functional recovery and bone mineral density. rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders. For more information, please visit www.insmed.com.
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
Insmed Incorporated, Richmond
Baxter Phillips, III, 804-565-3041